Copertina

No value of non‐selective beta‐blockers after TIPS‐insertion

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Anja Tiede, Lena Stockhoff, Hannah Rieland, Zhaoli Liu, Jim B. Mauz, Tammo L. Tergast, Martin A. Kabelitz, Sarah S. Schütte, Alena F. Ehrenbauer, Bernhard C. Meyer, Heiner Wedemeyer, Jan B. Hinrichs, Markus Cornberg, Christine S. Falk, Cheng‐Jian Xu, Benjamin Maasoumy
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
di: Christian Labenz, et al.
Pubblicazione: (2026)

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
di: Lisa Sandmann, et al.
Pubblicazione: (2024)

Altered Pathogen Spectrum of Spontaneous Bacterial Peritonitis in Patients Treated With Proton Pump Inhibitors
di: Philip Kitchen, et al.
Pubblicazione: (2026)

Plasma Ammonia Levels Predict Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement
di: Lisa Sandmann, et al.
Pubblicazione: (2025)

Expandable Constrained Transjugular Intrahepatic Portosystemic Shunt: An Individualised Approach for High‐Risk Patients?
di: Hannah Rieland, et al.
Pubblicazione: (2025)

Editorial: Non‐selective beta‐blockers: A lifesaving shield for critically ill patients with acute decompensation of cirrhosis?
di: Ling Yang, et al.
Pubblicazione: (2024)

Editorial: Stopping NUCs—When to Restart NUCs for the Best Outcome?
di: Melanie Urbanek‐Quaing, et al.
Pubblicazione: (2024)

Impact of non‐selective beta blockers on further decompensation and death in decompensated cirrhosis: Benefit and risk stratification by MELD score
di: Ting Wang, et al.
Pubblicazione: (2024)

Non‐selective beta‐blocker is associated with reduced mortality in critically ill patients with cirrhosis: A real‐world study
di: Rahul Kumar, et al.
Pubblicazione: (2024)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy
di: Mustafa Mohamedrashed, et al.
Pubblicazione: (2024)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy—Authors' reply
di: Annalisa Schiepatti, et al.
Pubblicazione: (2024)

Editorial: TIPS in the Era of Aging and Metabolic Comorbidity—Rethinking Risks and Rewards. Authors Reply
di: Michelle Spaan, et al.
Pubblicazione: (2026)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
di: Sai Kiran Kuchana, et al.
Pubblicazione: (2026)

Research Communication: The Cumulated Spontaneous Portosystemic Shunts ( SPSS ) Area Decreases After TIPS and Impacts on Prognosis
di: Marlene Hintersteininger, et al.
Pubblicazione: (2025)

Systematic review: Clinical phenotypes, histopathological features and prognosis of enteropathy due to angiotensin II receptor blockers
di: Annalisa Schiepatti, et al.
Pubblicazione: (2024)

Letter on ‘Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicentre Real‐World’
di: Silvia Nardelli, et al.
Pubblicazione: (2025)

Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicenter Real‐World Study
di: Yi Xiang, et al.
Pubblicazione: (2025)

Editorial: Three‐Dimensional (3D) Geometric Modelling in TIPS Implantation—A Further Step Toward Personalised Portal Pressure Reduction and Pre‐Procedural Planning. Authors' Reply
di: Markus Kimmann, et al.
Pubblicazione: (2025)

Featured Cover
di: Nina Løn, et al.
Pubblicazione: (2024)

Review article: Seeing Is Believing–The Eosinophilic Oesophagitis Endoscopic Reference Score Can Serve as a Valuable Clinical Trial Endpoint in Eosinophilic Oesophagitis
di: Ikuo Hirano, et al.
Pubblicazione: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
di: C. C. Mark Cheah, et al.
Pubblicazione: (2025)

Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management
di: Jakob B. Seidelin
Pubblicazione: (2024)

Letter: Bif195 for aspirin‐induced gastric mucosal damage – More to do in further research. Authors' reply
di: Nina Løn, et al.
Pubblicazione: (2024)

Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply
di: Nina Løn, et al.
Pubblicazione: (2024)

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH—Authors’ reply
di: S. K. Bansal, et al.
Pubblicazione: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
di: Elliot B. Tapper, et al.
Pubblicazione: (2024)

Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows?
di: J. M. B. W. Vos, et al.
Pubblicazione: (2025)

Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis—Hope Beyond Monotherapy
di: Ahmed B. Bayoumy, et al.
Pubblicazione: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
di: A. B. Fons, et al.
Pubblicazione: (2026)

Systematic Review: Variability in Definitions of Fibrostenosis in Eosinophilic Oesophagitis
di: Claire A. Beveridge, et al.
Pubblicazione: (2025)

Inflammatory bowel disease in 2024 and beyond
di: Richard B. Gearry, et al.
Pubblicazione: (2024)

Review article: Telecare in gastroenterology—Within the COVID‐19 pandemic and beyond
di: Fatima Hakak, et al.
Pubblicazione: (2024)

In Memoriam: Prof. Dr. Michael P. Manns (1951–2025)
di: Heiner Wedemeyer, et al.
Pubblicazione: (2025)

Editorial: Prevalence of Suspected Metabolic Dysfunction‐Associated Liver Disease in Adolescents in the United States Using Updated Diagnostic Criteria—Authors' Reply
di: Sheila L. Noon, et al.
Pubblicazione: (2025)

Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial
di: Elliot B. Tapper, et al.
Pubblicazione: (2024)

Editorial: UDCA Dosing in PBC—Between Guideline Adherence and Clinical Reality: Authors' Reply
di: Ellen Werner, et al.
Pubblicazione: (2026)

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
di: A. B. Fons, et al.
Pubblicazione: (2026)

Research Communication: Risk of Tuberculosis With Advanced Therapies in 20,705 Patients With Inflammatory Bowel Diseases in Low Incidence Regions—A U.S. Claims‐Based Study
di: Dhruv Ahuja, et al.
Pubblicazione: (2025)

Risk Factors for Liver Disease Cluster Geographically: A Precision Public Health Analysis of a UK City
di: R. Parker, et al.
Pubblicazione: (2025)

Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease
di: Benedikt Simbrunner, et al.
Pubblicazione: (2025)